Compound: Copanlisib
SMILES: O=C(NC1=Nc2c(OC)c(OCCCN3CCOCC3)ccc2C=4N1CCN4)c5cnc(N)nc5
InChIKey: PZBCKZWLPGJMAO-UHFFFAOYSA-N
Synonyms: Copanlisib, 1032568-63-0, BAY 80-6946, BAY-80-6946, BAY80-6946, BAY 80-6946 (Copanlisib), Aliqopa, 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide, 2-Amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-5-pyrimidinecarboxamide, MFCD18633201, WI6V529FZ9, Copanlisib (BAY 80-6946), C23H28N8O4, 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide, 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide, 2-amino-N-{7-methoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide, Copanlisib [INN], copanlisibum, UNII-WI6V529FZ9, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE, 2-amino-N-[7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide, Copanlisib tris-HCl, Copanlisib (Standard), COPANLISIB [MI], Copanlisib (USAN/INN), Copanlisib [USAN:INN], COPANLISIB [USAN], COPANLISIB [WHO-DD], Copanlisib(BAY80-6946), GTPL7875, orb1300871, SCHEMBL1655478, BAY 80-6946; Copanlisib, BAY-80-6946 tris-HCl, Copanlisib; BAY-80-6946, CHEMBL3218576, SCHEMBL13084037, SCHEMBL13084039, SCHEMBL28895762, BAY 80-6946(Copanlisib)?, DTXSID00145728, CHEBI:173077, PZBCKZWLPGJMAO-UHFFFAOYSA-N, GLXC-90533, EX-A2005, BDBM50204093, EBC-17129, HY-15346R, NSC760443, NSC800076, NSC809693, NSC816437, s2802, AKOS025290222, BAY-806946, CS-0741, DB12483, NSC-760443, NSC-800076, NSC-809693, NSC-816437, PB22956, VS-0128, NCGC00346457-01, NCGC00346457-02, NCGC00346457-04, NCGC00346457-05, AC-28438, BAY 80-6946?, BC164810, BP-43635, HY-15346, SY108807, NS00072920, D10867, BRD-K24666289-001-02-3, BRD-K24666289-001-04-9, Q19903876, 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide, 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1.2-c]quinazolin-5-yl]pyrimidine-5-carboxamide, 2-amino-N-[7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide, 5-PYRIMIDINECARBOXAMIDE, 2-AMINO-N-(2,3-DIHYDRO-7-METHOXY-8-(3-(4-MORPHOLINYL)PROPOXY)IMIDAZO(1,2-C)QUINAZOLIN-5-YL)-
Theoretical properties:
molecular_formula: C23H28N8O4
molecular_weight: 480.5 g/mol
exact_mass: 480.22335140 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 9
rotatable_bond_count: 7
heavy_atom_count: 35
topological_polar_surface_area: 140 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Copanlisib is an imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies. It has a role as an antineoplastic agent, an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor and an apoptosis inducer. It is a secondary carboxamide, an aromatic ether, an aminopyrimidine, a member of morpholines, a diether, an imidazoquinazoline, a pyrimidinecarboxamide and a tertiary amino compound.
chebi: An imidazoquinazoline that is 2,3-dihydroimidazo[1,2-<em>c</em>]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies.
chembl: COPANLISIB is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
In November 2023, Bayer announced that it was withdrawing copanlisib from the US market.